Interestingly, due to its unique binding mode, sonrotoclax can inhibit the G101V BCL2 variant and kill mutant cells.338,339 There are currently seven active phase I and II clinical trials involving sonrotoclax monotherapy for the treatment of mature B cell malignancies, R/R CLL and SLL, R/R MCL, myeloid malignancies and Waldenström Macroglobulinemia. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.